Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Paclitaxel and epirubicin
Drug: Paclitaxel plus carboplatin

First Posted Date: 2011-01-13

Last Posted Date: 2011-11-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 80

Registration Number: NCT01276769

Locations: 🇨🇳
Cancer institute &Hospital，Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients

Phase 1

Completed

Conditions: Rectal Neoplasms

Interventions: Drug: Capecitabine

First Posted Date: 2011-01-04

Last Posted Date: 2015-04-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 18

Registration Number: NCT01268943

Locations: 🇨🇳
radiation department, Cancer Hospital, CAMS, Beijing, Beijing, China

The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: cisplatin

First Posted Date: 2010-08-24

Last Posted Date: 2020-07-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 84

Registration Number: NCT01187238

Locations: 🇨🇳
Zhejiang province cancer hospital, Hangzhou, Zhejiang, China
🇨🇳
Cancer hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Cancer hospital, Chinese Academy of Medical Sciences, Beijing, China

Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer

Phase 2

Conditions: Gastric Cancer
Concurrent Chemoradiotherapy

Interventions: Drug: nimotuzumab

First Posted Date: 2010-08-12

Last Posted Date: 2013-09-19

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT01180166

Locations: 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy

Phase 3

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Radiation: 3D-CRT based Involved Field Radiotherapy

First Posted Date: 2010-07-02

Last Posted Date: 2010-07-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 400

Registration Number: NCT01156259

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: TP
Drug: EC-T

First Posted Date: 2010-06-25

Last Posted Date: 2021-02-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 320

Registration Number: NCT01150513

Locations: 🇨🇳
Cancer Institute & Hospital Chinese Academy of Medical Sciences, Beijing, China

Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer

Phase 4

Completed

Conditions: Locally Advanced Malignant Neoplasm

Interventions: Drug: pemetrexed plus cisplatin

First Posted Date: 2010-06-15

Last Posted Date: 2013-03-14

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 28

Registration Number: NCT01143974

Locations: 🇨🇳
Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, China

Felodipine Event Reduction Study

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Felodipine

First Posted Date: 2010-06-04

Last Posted Date: 2010-06-25

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 9800

Registration Number: NCT01136863

Locations: 🇨🇳
Fu Wai Hospital, Beijing, China

Regimens Comparison for Breast Cancers of Positive Lymph Nodes

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Epirubicin, CTX, Paclitaxel
Drug: Epirubicin, Paclitaxel

First Posted Date: 2010-06-02

Last Posted Date: 2013-03-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 1000

Registration Number: NCT01134523

Locations: 🇨🇳
Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, China

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Phase 3

Conditions: Carcinoma, Invasive Ductal, Breast

Interventions: Drug: Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine
Drug: Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine

First Posted Date: 2010-05-19

Last Posted Date: 2011-05-04

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 200

Registration Number: NCT01126138

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy